Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
David Planchard, Sanjay Popat, Keith M. Kerr et al. · Annals of Oncology · 2018
Cited by 2,274 works. doi:10.1093/annonc/mdy275 Open-access PDF
Authors
- David Planchard
- Sanjay Popat
- Keith M. Kerr
- Silvia Novello
- Egbert Frederik Smit
- Corinne Faivre Finn
- Tony S.K. Mok
- Martin Reck
- Paul Emile Van Schil
- Matthew David Hellmann
- Solange Peters
References
- Global cancer statistics
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- AJCC Cancer Staging Manual
- Cancer Incidence in Five Continents
- Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib
- EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
- Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
- Comparison of Four Chemotherapy Regimens for Advanced Non–Small-Cell Lung Cancer
- Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer